Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAUR | Q03405 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.60 |
| ▸ | RAB9A | P51151 | 9/20 | 0.60 |
| ▸ | NPC1 | O15118 | 8/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | KHK | P50053 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PYGM | P11217 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31495003 | 0.77 | ALDH1A1 (0.58) | KDM4ERAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL29010071 | 0.76 | PLAUR (0.61) | PLAURKDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL30682553 | 0.76 | PLAUR (1.00) | PLAURKDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL30170557 | 0.76 | PLAUR (0.61) | PLAURKDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL1029154 | 0.76 | PLAUR (0.61) | PLAURKDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL29124805 | 0.76 | PLAUR (0.61) | PLAURKDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL16403339 | 0.76 | PLAUR (0.61) | PLAURKDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL1589916 | 0.76 | PLAUR (0.61) | PLAURKDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL28487096 | 0.76 | PLAUR (0.61) | PLAURKDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL30617972 | 0.76 | PLAUR (0.61) | PLAURKDM4ERAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107973755-B | Preparation method of 3-acetamido quinoxalinone derivative | 滨州学院 | 2020-12-29 | — | — | CN | disclosed |
| CN-111825717-A | Crystalline forms of 5-chloro-N4- [2- (dimethylphosphoryl) phenyl ] -N2- { 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } pyrimidine-2, 4-diamine | 阿瑞雅德制药公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| CN-107108559-B | Crystalline forms of 5-chloro-N4- [2- (dimethylphosphoryl) phenyl ] -N2- { 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } pyrimidine-2, 4-diamine | 阿瑞雅德制药公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-107235923-B | Preparation method of 3-aryl quinoxalinone derivatives | 河南工业大学 | 2020-01-21 | — | — | CN | disclosed |
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9598447-B2 | Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598411-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-3101018-A1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma L.P. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| EP-1615613-A4 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1615613-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040266668-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004093798-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266668-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, CTSC | PLAUR 1374/4885KDM4E 856/4885RAB9A 2677/4885 |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | PLAUR 753/4885KDM4E 1405/4885RAB9A 2683/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | PLAUR 1436/4885KDM4E 691/4885RAB9A 2534/4885 |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, HPN | PLAUR 1256/4885KDM4E 765/4885RAB9A 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.